Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor recep (Q48676732)
Jump to navigation
Jump to search
scientific article published in March 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor recep |
scientific article published in March 2011 |
Statements
1 reference
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor recep (English)
1 reference
1 reference
Flavia Longo
1 reference
Gabriella Farina
1 reference
Olga Martelli
1 reference
Ida Pavese
1 reference
Andrea Mancuso
1 reference
Luca Moscetti
1 reference
Alessandro Bertolini
1 reference
Enrico Cortesi
1 reference
Antonio Farris
1 reference
Daniele Fagnani
1 reference
Maria Cristina Locatelli
1 reference
Giuseppe Valmadre
1 reference
Antonio Ardizzoia
1 reference
Maurizio Tomirotti
1 reference
Eliana Rulli
1 reference
Marina Chiara Garassino
1 reference
Alberto Scanni
1 reference
1 March 2011
1 reference
1 reference
12
1 reference
2
1 reference
138-141
1 reference